EP2480287A2 - Association de tiotropium sous forme de poudre sèche - Google Patents

Association de tiotropium sous forme de poudre sèche

Info

Publication number
EP2480287A2
EP2480287A2 EP10787588A EP10787588A EP2480287A2 EP 2480287 A2 EP2480287 A2 EP 2480287A2 EP 10787588 A EP10787588 A EP 10787588A EP 10787588 A EP10787588 A EP 10787588A EP 2480287 A2 EP2480287 A2 EP 2480287A2
Authority
EP
European Patent Office
Prior art keywords
medicament composition
dry powder
tiotropium
nedocromil
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10787588A
Other languages
German (de)
English (en)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2480287A2 publication Critical patent/EP2480287A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Abstract

L'invention concerne une composition pharmaceutique contenant du tiotropium préparé avec une quantité efficace d'un dérivé de cromolyn utilisé pour le traitement de maladies respiratoires par voie d'inhalation.
EP10787588A 2009-09-23 2010-09-22 Association de tiotropium sous forme de poudre sèche Withdrawn EP2480287A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2009/07237A TR200907237A2 (tr) 2009-09-23 2009-09-23 Tiotropyum kuru toz kombinasyonu
PCT/TR2010/000184 WO2011037550A2 (fr) 2009-09-23 2010-09-22 Combinaison de poudre sèche de tiotropium

Publications (1)

Publication Number Publication Date
EP2480287A2 true EP2480287A2 (fr) 2012-08-01

Family

ID=43643869

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10787588A Withdrawn EP2480287A2 (fr) 2009-09-23 2010-09-22 Association de tiotropium sous forme de poudre sèche

Country Status (3)

Country Link
EP (1) EP2480287A2 (fr)
TR (1) TR200907237A2 (fr)
WO (1) WO2011037550A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475467B1 (en) * 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8712251D0 (en) * 1987-05-23 1987-07-01 Fisons Plc Formulation
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GB9006233D0 (en) 1990-03-20 1990-05-16 Kenrick & Jefferson Ltd Forms,for use,for example,as parking tickets
GB0009592D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
YU33103A (sh) * 2000-10-31 2006-05-25 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Formulacija rastvora za inhalaciju sa soli tiotropijuma
WO2006076222A2 (fr) * 2005-01-10 2006-07-20 Glaxo Group Limited Formulations pharmaceutiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475467B1 (en) * 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011037550A2 *

Also Published As

Publication number Publication date
WO2011037550A2 (fr) 2011-03-31
TR200907237A2 (tr) 2011-04-21
WO2011037550A3 (fr) 2011-09-15

Similar Documents

Publication Publication Date Title
EP2600830B1 (fr) Formulation de poudre sèche comprenant un inhibiteur de phosphodiestérase
EP2528585B1 (fr) Compositions pharmaceutiques comprenant du tiotropium, du formotérol et du budésonide
EP2528596B1 (fr) Composition sous forme de poudre sèche pour administration par inhalation comprenant une combinaison de bromure de tiotropium, de xynafoate de salmeterol et de propionate de fluticasone.
EP2533777B1 (fr) Compositions pharmaceutiques contenant de la fluticasone, du tiotropium et du cromoglycate de sodium
WO2011136754A1 (fr) Médicament mis au point pour le traitement de maladies respiratoires
WO2009090008A1 (fr) Formulation de poudre sèche comprenant un médicament anticholinergique
WO2011093819A2 (fr) Nouvelle composition pharmaceutique combinée comprenant du tiotropium
WO2011093820A2 (fr) Composition pharmaceutique combinée comprenant du tiotropium
EP2563364A1 (fr) Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires
EP2480203B1 (fr) Formulation de poudre sèche de tiotropium contenue dans une bande alvéolée thermoformée
JP2012530134A (ja) 呼吸器疾患治療における併用療法及び吸入薬剤としてのｒ型バンブテロールの使用
EP2515848B1 (fr) Combinaison de poudre sèche constituée de tiotropium, d'un corticostéroïde et d'un dérivé d'acide cromoglicique
EP2515845B1 (fr) Formulation de poudre sèche comprenant du tiotropium, du formoterol et un derive d'acide cromoglicine
WO2011078817A1 (fr) Poudre séche combinant tiotropium, mométasone et un dérivé d'acide cromoglicique
EP2515846B1 (fr) Combinaison de tiotropium, budesonide et acide cromoglicique en composition de poudre sèche
WO2011037550A2 (fr) Combinaison de poudre sèche de tiotropium
EP2515888B1 (fr) Poudre sèche pour inhalation comprenant tiotropium
EP2528597B1 (fr) Composition sous form de poudre sèche comprenant une combinaison de bromure de tiotropium, fumarate de formoterol et de furoate de mometasone
US8834931B2 (en) Dry powder formulation containing tiotropium for inhalation
WO2011049539A1 (fr) Compositions comprenant un corticostéroïde, un agoniste bêta2 et de l'acide cromoglicique ou du nédocromil
WO2011093812A2 (fr) Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche
WO2011136752A1 (fr) Composition pharmaceutique combinée comprenant du carmotérol et du ciclésonide pour le traitement de maladies respiratoires
US20130022650A1 (en) Compositions containing salmeterol, fluticasone and cromoglicic acid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120411

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160215

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160628